Christopher L. Corless

51.6k total citations · 15 hit papers
321 papers, 31.0k citations indexed

About

Christopher L. Corless is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Surgery. According to data from OpenAlex, Christopher L. Corless has authored 321 papers receiving a total of 31.0k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Pulmonary and Respiratory Medicine, 108 papers in Gastroenterology and 91 papers in Surgery. Recurrent topics in Christopher L. Corless's work include Gastrointestinal Tumor Research and Treatment (105 papers), Sarcoma Diagnosis and Treatment (79 papers) and Gastrointestinal disorders and treatments (41 papers). Christopher L. Corless is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (105 papers), Sarcoma Diagnosis and Treatment (79 papers) and Gastrointestinal disorders and treatments (41 papers). Christopher L. Corless collaborates with scholars based in United States, Canada and India. Christopher L. Corless's co-authors include Michael C. Heinrich, Jonathan A. Fletcher, Christopher D.�M. Fletcher, Brian P. Rubin, George D. Demetri, Charles D. Blanke, Ajia Town, Laura McGreevey, Heikki Joensuu and Margaret von Mehren and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Christopher L. Corless

317 papers receiving 30.1k citations

Hit Papers

Diagnosis of gastrointestinal stromal tumors: A consensus... 2002 2026 2010 2018 2002 2003 2003 2004 2007 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Diagnosis of gastrointestinal stromal tumors: A consensus approach
    2002 2.5k citations Christopher D.�M. Fletcher, Christopher L. Corless et al. Human Pathology profile →
  2. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
    2003 1.8k citations Michael C. Heinrich, Christopher L. Corless et al. Science profile →
  3. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
    2003 1.7k citations Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology profile →
  4. Biology of Gastrointestinal Stromal Tumors
    2004 906 citations Christopher L. Corless, Jonathan A. Fletcher et al. Journal of Clinical Oncology profile →
  5. Gastrointestinal stromal tumour
    2007 813 citations Brian P. Rubin, Michael C. Heinrich et al. profile →
  6. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
    2008 750 citations Charles D. Blanke, George D. Demetri et al. Journal of Clinical Oncology profile →
  7. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
    2005 626 citations Christopher L. Corless, Diana Griffith et al. Journal of Clinical Oncology profile →
  8. Gastrointestinal stromal tumours: origin and molecular oncology
    2011 624 citations Christopher L. Corless, Christine M. Barnett et al. profile →
  9. Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
    2006 609 citations Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology profile →
  10. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
    2008 564 citations Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology profile →
  11. Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
    2010 500 citations Christopher L. Corless, Charles D. Blanke et al. Journal of Clinical Oncology profile →
  12. The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status
    2004 487 citations Christopher L. Corless, Brian P. Rubin et al. profile →
  13. Gastrointestinal stromal tumour
    2013 460 citations Heikki Joensuu, Christopher L. Corless et al. profile →
  14. Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
    2017 451 citations Christopher L. Corless et al. profile →
  15. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
    2008 436 citations Michael C. Heinrich, Kouros Owzar et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher L. Corless United States 86 17.0k 15.3k 9.9k 6.3k 5.9k 321 31.0k
Michael C. Heinrich United States 82 17.5k 1.0× 17.2k 1.1× 8.4k 0.9× 6.2k 1.0× 5.7k 1.0× 376 32.2k
Robert G. Maki United States 88 18.3k 1.1× 8.0k 0.5× 5.3k 0.5× 3.9k 0.6× 9.7k 1.7× 377 26.3k
Raf Sciot Belgium 81 12.5k 0.7× 5.0k 0.3× 4.6k 0.5× 4.6k 0.7× 5.2k 0.9× 555 24.8k
Brian P. Rubin United States 67 11.1k 0.7× 7.3k 0.5× 5.2k 0.5× 3.6k 0.6× 4.2k 0.7× 275 19.2k
Pancras C.W. Hogendoorn Netherlands 85 15.7k 0.9× 2.9k 0.2× 4.0k 0.4× 5.1k 0.8× 6.9k 1.2× 443 26.7k
Jason L. Hornick United States 82 11.6k 0.7× 2.4k 0.2× 5.1k 0.5× 4.5k 0.7× 8.3k 1.4× 487 24.8k
John R. Goldblum United States 79 12.4k 0.7× 4.1k 0.3× 9.7k 1.0× 2.0k 0.3× 5.7k 1.0× 362 22.7k
Christopher D.�M. Fletcher United States 125 41.3k 2.4× 14.4k 0.9× 15.0k 1.5× 10.0k 1.6× 20.1k 3.4× 674 70.0k
Angelo Paolo Dei Tos Italy 67 10.9k 0.6× 2.5k 0.2× 3.4k 0.3× 2.5k 0.4× 6.1k 1.0× 438 17.0k
David S. Klimstra United States 117 10.4k 0.6× 2.2k 0.1× 19.1k 1.9× 7.0k 1.1× 34.2k 5.8× 490 48.6k

Countries citing papers authored by Christopher L. Corless

Since Specialization
Citations

This map shows the geographic impact of Christopher L. Corless's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher L. Corless with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher L. Corless more than expected).

Fields of papers citing papers by Christopher L. Corless

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher L. Corless. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher L. Corless. The network helps show where Christopher L. Corless may publish in the future.

Co-authorship network of co-authors of Christopher L. Corless

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher L. Corless. A scholar is included among the top collaborators of Christopher L. Corless based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher L. Corless. Christopher L. Corless is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wood, Matthew D., Carol Beadling, Tanaya Neff, et al.. (2023). Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences. Acta Neuropathologica Communications. 11(1). 143–143. 3 indexed citations
2.
Forquer, Isaac, Ajia Town, Lillian R. Klug, et al.. (2017). Biochemical, Molecular, and Clinical Characterization of Succinate Dehydrogenase Subunit A Variants of Unknown Significance. Clinical Cancer Research. 23(21). 6733–6743. 11 indexed citations
3.
Carvajal, Richard D., Donald P. Lawrence, Jeffrey S. Weber, et al.. (2015). Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research. 21(10). 2289–2296. 97 indexed citations
4.
Corless, Christopher L., Karla V. Ballman, Cristina R. Antonescu, et al.. (2014). Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 32(15). 1563–1570. 210 indexed citations
5.
Javidi‐Sharifi, Nathalie, Elie Traer, Jacqueline Martinez, et al.. (2014). Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75(5). 880–891. 86 indexed citations
6.
Barnett, Christine M., Michael C. Heinrich, Jeong Ho Lim, et al.. (2013). Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. Clinical Cancer Research. 20(5). 1306–1312. 19 indexed citations
7.
Ang, Daphne, et al.. (2013). Frequent PIK3CA Mutations in Radial Scars. Diagnostic Molecular Pathology. 22(4). 210–214. 15 indexed citations
8.
Kehr, Elizabeth, Julie M. Jorns, Daphne Ang, et al.. (2012). Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Human Pathology. 43(12). 2207–2212. 31 indexed citations
9.
George, Suzanne, Qian Wang, Michael C. Heinrich, et al.. (2012). Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology. 30(19). 2401–2407. 200 indexed citations
10.
Si, Lu, Yanyan Zhu, Xiaowei Xu, et al.. (2011). Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma. Clinical Cancer Research. 17(7). 1684–1691. 181 indexed citations
11.
Dumont, Agathe, Lori Rink, Andrew K. Godwin, et al.. (2011). A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Annals of Oncology. 23(5). 1335–1340. 33 indexed citations
12.
Pantaleo, Maria A., Annalisa Astolfi, Margherita Nannini, et al.. (2011). Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology. 59(6). 1071–1080. 20 indexed citations
13.
Heinrich, Michael C., Robert G. Maki, Christopher L. Corless, et al.. (2008). Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 26(33). 5352–5359. 564 indexed citations breakdown →
14.
Sabo, Edmond, Patricia A. Meitner, Rosemarie Tavares, et al.. (2008). Expression Analysis of Barrett's Esophagus–Associated High-Grade Dysplasia in Laser Capture Microdissected Archival Tissue. Clinical Cancer Research. 14(20). 6440–6448. 26 indexed citations
15.
16.
Coffey, Robert J., M. Kay Washington, Christopher L. Corless, & Michael C. Heinrich. (2007). Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. Journal of Clinical Investigation. 117(1). 70–80. 87 indexed citations
17.
Heinrich, Michael C., Charles D. Blanke, Christopher L. Corless, & Brian Druker. (2003). PDGF Receptors as Therapeutic Targets. The Indian Journal of Medical Research. 55(11). 1259–72. 1 indexed citations
18.
Heinrich, Michael C., Christopher L. Corless, Anette Duensing, et al.. (2003). PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science. 299(5607). 708–710. 1767 indexed citations breakdown →
19.
Dinulescu, Daniela M., Lisa J. Wood, Lei Shen, et al.. (2003). c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 22(55). 8852–8860. 12 indexed citations
20.
Fennerty, M. Brian, Christopher L. Corless, Brett C. Sheppard, et al.. (2001). Pathological documentation of complete elimination of Barrett's metaplasia following endoscopic multipolar electrocoagulation therapy. Gut. 49(1). 142–144. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael C. Heinrich Breakdown of academic impact, for papers by Robert G. Maki Breakdown of academic impact, for papers by Raf Sciot Breakdown of academic impact, for papers by Brian P. Rubin Breakdown of academic impact, for papers by Pancras C.W. Hogendoorn Breakdown of academic impact, for papers by Jason L. Hornick Breakdown of academic impact, for papers by John R. Goldblum Breakdown of academic impact, for papers by Christopher D.�M. Fletcher Breakdown of academic impact, for papers by Angelo Paolo Dei Tos Breakdown of academic impact, for papers by David S. Klimstra
Rankless by CCL
2026